Hybrimax, a San Diego-based joint-venture between Genautica and Multimeric Biotherapeutics is working on developing a method for stimulating B cells in vitro in conjunction with a method for producing monoclonal antibodies such that the process of producing monoclonal antibodies is highly facilitated.